MagVenture Revenue and Competitors
Estimated Revenue & Valuation
- MagVenture's estimated annual revenue is currently $7.5M per year.
- MagVenture's estimated revenue per employee is $50,676
Employee Data
- MagVenture has 148 Employees.
- MagVenture grew their employee count by 9% last year.
MagVenture's People
Name | Title | Email/Phone |
---|
MagVenture Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.5M | 148 | 9% | N/A | N/A |
#2 | N/A | 71 | -7% | N/A | N/A |
#3 | $7.5M | 270 | 10% | N/A | N/A |
#4 | N/A | 82 | -22% | N/A | N/A |
#5 | N/A | 411 | 14% | N/A | N/A |
#6 | N/A | 71 | -3% | N/A | N/A |
#7 | N/A | 1463 | 5% | N/A | N/A |
What Is MagVenture?
MagVenture® is a medical device manufacturer of world leading magnetic stimulation systems. From its headquarters in Denmark, MagVenture® develops and markets advanced medical equipment based on the use of pulsating magnetic fields for clinical examination as well as for research in the areas of psychiatry, neurophysiology, neurology, cognitive neuroscience, and rehabilitation. MagVenture’s product line MagPro® is designed especially for the needs of researchers and healthcare professionals. With 7 different magnetic stimulators and +30 different coils, the MagPro line provides a solution to most stimulation needs. MagVenture TMS Therapy® is CE approved for the treatment of Major Depressive Disorder, OCD and Addiction (PSUD). Furthermore, MagVenture TMS Therapy can reduce the symptoms of Comorbid Anxiety in patients suffering from depression. For the US: FDA cleared for treatment of Major Depressive Disorder - (Standard TMS) MagPro® stimulators R20, R30, R30 with MagOption, X100, and X100 with MagOption are all FDA 510(k) cleared for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode (k170114, k150641 and k171481). FDA cleared for treatment of Major Depressive Disorder – (Theta Burst) MagPro® stimulators R30 with theta burst option, X100 and X100 with MagOption are all FDA 510(k) cleared for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode (k173620) FDA cleared for adjunct treatment of Obsessive-Compulsive Disorder MagPro stimulators R30, R30 with MagOption, X100 and X100 with MagOption are all FDA 510 (k) cleared as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD) (k193006) For more information please visit www.magventure.com
keywords:N/AN/A
Total Funding
148
Number of Employees
$7.5M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $69.3M | 192 | 47% | N/A |